Asuragen introduces our latest NGS-in-a-Box^™ assay product for analysis of fusion and exon skipping events important to NSCLC diseases –
QuantideX® NGS RNA Lung Cancer Kit (RUO)

Major Highlights & Advantages

• Asuragen’s industry-first NGS-in-a-Box™ assay kits are uniquely configured for an end-to-end (sample-to-data) NGS workflow:
  • All sequencing library preparation materials and reagents
  • Data analysis solution
• Highly efficient workflowHands-on time ~2.25h (24 samples)
  • Sample indexing ≥48 per MiSeq flowcell (v3 kit)
  • Optimized to handle low RNA input from FFPE or FNA samples
• Comprehensive coverage of fusion and exon skipping events important to NSCLC disease: Fusion targets (110) Exon skipping events (MET exon 14)
• Detect other fusion events with 3’-5’ imbalances in: ALK, RET, ROS1, and NTRK1
• Includes mRNA gene expression markers (24)

*For Research Use Only. Not for use in diagnostic procedures.